Trial · NCT00617903
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward) | Baseline and End of Study (Week 12) | |
| Primary | Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Study (LOCF) | At End of Study (Week 12) | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1). |
| Primary | Grouped Change From Baseline in Erythema Intensity Score at End of Study (LOCF) | Baseline and End of Study (Week 12) | Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Mean of Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF) | At Weeks 4, 8, 12 and End of Study (LOCF) | |
| Secondary | Nominal Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8 and 12 | Baseline and Weeks 4, 8 and 12 | |
| Secondary | Percent Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF) | Baseline and Weeks 4, 8, 12 and End of Study (LOCF) | |
| Secondary | Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF) | At Weeks 4, 8, 12 and End of Study (LOCF) | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1). |
| Secondary | Change From Baseline in IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF) | Baseline and Weeks 4, 8, 12 and End of Study (LOCF) | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1). |
| Secondary | Percentage of Participants With Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF) | At Weeks 4, 8, 12 and End of Study (LOCF) | Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Change From Baseline in Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF) | Baseline and Weeks 4, 8, 12 and End of Study (LOCF) | Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Grouped Change From Baseline in Erythema Intensity Score at Weeks 4, 8 and 12 | Baseline and Weeks 4, 8 and 12 | Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Percentage of Participants With Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF) | At Weeks 4, 8, 12 and End of Study (LOCF) | Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF) | Baseline and Weeks 4, 8, 12 and End of Study (LOCF) | Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Grouped Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF) | Baseline and Weeks 4, 8, 12 and End of Study (LOCF) | Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe |
| Secondary | Investigator's Rating of Overall Improvement at End of Study | At End of Study (Week 12) | Investigator's rating of overall improvement: 1 - excellent improvement; 2 - marked improvement; 3 - moderate improvement; 4 - no change; 5 - deterioration |
| Secondary | Patients' Rating of Overall Improvement at End of Study | At End of Study (Week 12) | Patient's rating of overall improvement: 1 - excellent; 2 - good; 3 - fair; 4 - no improvement; 5 - worse |
| Secondary | Patients' Opinion on Cosmetic Acceptability at End of Study | At End of Study (Week 12) | Patient's opinion on cosmetic acceptability: 1 - very good; 2 - good; 3 - satisfactory; 4 - poor; 5 - no opinion |
| Secondary | Percentage of Participants With IGA Based Therapeutic Success at Weeks 4, 8 and 12 | At Weeks 4, 8 and 12 | IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success was defined as an IGA score of clear or minimal (0 to 1)."). |
| Secondary | Percentage of Participants With IGA Based Patient Response at Weeks 4, 8, 12 and End of Study (LOCF) | At Weeks 4, 8, 12 and End of Study (LOCF) | IGA based Patient response was defined as an IGA score of clear, minimal or mild (0, 1, 2). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00617903/registered